Practical considerations when generalizing study results: a potential outcomes perspective

Catherine R. Lesko
L. Buchanan
University of Rhode Island, buchanan@uri.edu
Daniel Westreich
Jessie K. Edwards
Michael G. Hudgens

See next page for additional authors

Follow this and additional works at: https://digitalcommons.uri.edu/php_facpubs

The University of Rhode Island Faculty have made this article openly available. Please let us know how Open Access to this research benefits you.

Terms of Use
This article is made available under the terms and conditions applicable towards Open Access Policy Articles, as set forth in our Terms of Use.

Citation/Publisher Attribution
Available at: http://dx.doi.org/10.1097/EDE.0000000000000664

This Article is brought to you for free and open access by the Pharmacy Practice at DigitalCommons@URI. It has been accepted for inclusion in Pharmacy Practice Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact digitalcommons-group@uri.edu.
Practical considerations when generalizing study results: a potential outcomes perspective

Authors

The University of Rhode Island Faculty have made this article openly available. Please let us know how Open Access to this research benefits you.

This is a pre-publication author manuscript of the final, published article.

Terms of Use
This article is made available under the terms and conditions applicable towards Open Access Policy Articles, as set forth in our Terms of Use.

This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/php_facpubs/92
Practical considerations when generalizing study results: a potential outcomes perspective

Catherine R. Lesko\textsuperscript{1,2}
Ashley L. Buchanan\textsuperscript{3,4}
Daniel Westreich\textsuperscript{1}
Jessie K. Edwards\textsuperscript{1}
Michael G. Hudgens\textsuperscript{3}
Stephen R. Cole\textsuperscript{1}

\textsuperscript{1}Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC
\textsuperscript{2}Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
\textsuperscript{3}Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC
\textsuperscript{4}Department of Epidemiology, TH Chan School of Public Health, Harvard University, Boston, MA

Keywords: Causality; Effect modifier, epidemiologic; Selection bias; Sampling studies
Abstract

Great care is generally taken in epidemiologic studies to ensure the internal validity of causal effect estimates; however, the external validity of effect estimates, has received considerably less attention. The causal effect in a given target population is the average of heterogeneous subgroup effects, weighted according to the prevalence of the subgroups in the target population. When the study sample is not a random sample of the target population, the sample average treatment effect, even if internally valid, cannot be expected to equal the average treatment effect in the target population. There are several categories of choices for the target population. The study sample may be a census of the target population; the population from which the study sample is a random sample or from which the study sample is not a random sample; or some other population of which, the study sample is not a subset of the target population. The identification conditions sufficient for external validity closely parallel the identification conditions for internal validity, namely: conditional exchangeability; positivity; similar distributions of the versions of; similar patterns of interference; no measurement error; and correct model specification. The value of an effect estimate for planning purposes and decision making will depend on the degree of departure from both internal and external validity. If the study sample is not a random sample of the target population, direct standardization (the g-formula or transport formula) or inverse probability weighting can be used to estimate a causal effect in the target population.
Epidemiology as a discipline is distinguished by its efforts to identify causes of disease for the purpose of intervening to improve public health. Great care is generally taken in epidemiologic studies to ensure the internal validity of causal effect estimates, including the application of methods to minimize the potential for bias due to measurement error, confounding, selection (specifically, due to missing data, including censoring and truncation), and model misspecification. However, the external validity of effect estimates, has received considerably less attention. For the purposes of this discussion, we use the term external validity to refer to the potential for an internally valid treatment (or exposure or intervention) effect measured in a study sample to differ from the treatment effect that would have been estimated in the population of interest (henceforth, the target population). External validity encompasses generalizability and transportability, which we distinguish below. We advance the discussion of external validity herein using a potential outcomes framework. We enumerate a set of identification assumptions sufficient to estimate an externally valid effect, and note the parallel between these and the identification assumptions sufficient to estimate an internally valid effect. Finally, we illustrate some issues regarding generalizability with a simple example and discuss practical considerations for addressing generalizability in epidemiological study design.

Definitions and causal framework

A well-defined causal question states the outcome(s) of interest, denoted by $Y$; the treatments of interest, denoted by $A$; and the target population, of size $N$. 

Generalizability Definitions
described by a set of characteristics denoted by $W$. Here, we assume variables in $W$ are discrete, however, all concepts are easily extended to the case of continuous $W$.

The causal effect of interest is a contrast (i.e., a difference or ratio) of the distribution of potential outcomes, $Y(a)$, in the target population under two different interventions, treatments, or policies of interest, for example:

$$E_T\{E[Y(a)|W]P_T(W)\} - E_T\{E[Y(a')|W]P_T(W)\}$$  \hspace{1cm} (1)$$

where $Y(a)$ denotes the outcome that a participant would have if he or she received treatment $a$, and the subscript $T$ denotes that the set of characteristics $W$ takes the distribution seen in target population. This notation makes it clear that the overall causal effect in the target population is the average of effects that are heterogeneous according to $W$, with weights defined by the distribution of $W$ in the target population, $P_T(W)$. $P_T(W)$ is often omitted when the causal effect of interest is written (i.e. $E[Y(a)] - E[Y(a')]$) under the implicit assumption that either 1) the study sample is a census of the target population; 2) the study sample is a simple random sample from the target population, i.e., the distribution of $W$ in the study sample, denoted $P_S(W)$, is equal to $P_T(W)$ in expectation; 3) there is a distinct target population, $M$, of which the study sample is not a proper subset, for which $P_M(W)$ is equal to $P_S(W)$; or 4) the causal effect is homogeneous across all $W$ for the causal contrast of interest.

It is helpful to distinguish threats to validity that arise after enumeration of the study sample, which we define as threats to internal validity, from threats to validity due to eligibility and enrollment of study subjects, which we define as threats to external validity. We define an estimator as internally valid when the
estimator of association in the study sample is a consistent estimator of the
treatment effect in the source population from which the study participants are
randomly sampled (the sample average treatment effect). The distribution of $W$ in
the study sample, $P_S(W)$, may differ from $P_T(W)$ without threatening internal
validity. We define a causal estimator to be *externally* valid when the sample
average treatment effect is a consistent estimator of the average treatment effect in
the target population (population average treatment effect). An estimate will be
externally valid under one of the first three scenarios described above, all of which
result in the distribution of $W$ in the study sample being equal to the distribution of
$W$ in the target population.

**Assumptions**

Given we cannot observe all potential outcomes for subjects in our target
population or our study sample,\textsuperscript{3,4} we can rely on a sufficient set of identification
assumptions under which (with a consistent estimator) an estimate of association
could be interpreted causally.

These assumptions are well described in the literature for estimating an
internally valid causal estimate. They include: 1) the unexposed are a good
substitute for the experience of the exposed in the absence of exposure and vice
versa (exchangeability), perhaps conditional on a set of covariates, $Z$ (conditional
exchangeability); 2) a non-zero probability of exposure within every stratum
defined by $Z$ (positivity); 3) treatment variation irrelevance or no versions of
treatment (sometimes referred to as consistency);\textsuperscript{5-8} 4) no interference or partial
interference (or some other restriction on the interference structure);\textsuperscript{9,10} 5) no measurement error; and 6) if \(Z\) is high dimensional and non-parametric inference is unfeasible, correct specification of parametric models.

The identification conditions sufficient for external validity closely parallel the identification conditions for internal validity.\textsuperscript{18,27} First, we assume that the participants included in the sample are exchangeable with members of the target population who were not sampled, perhaps conditional on \(W\) (conditional exchangeability):

\[
S \perp [Y(a), Y(a')]|W
\]

where \(S\) is an indicator of enrollment into the study sample. Enrollment into the sample is both under the control of the researcher (in designing a recruitment strategy) and under the control of the participants (in deciding whether to provide consent to participate). For the purposes of identification of the causal contrast in the target population, the set of characteristics, \(W\), is sufficient if it includes all causes of (or proxies for causes of) sampling and the outcome. If the researcher is willing to specify a single causal contrast of interest, then the set of characteristics \(W\) may be restricted to a subset of \(W\) that are effect measure modifiers of that contrast.\textsuperscript{2} Second, we assume that, within strata of \(W\), all subjects in the target population have some probability of being selected into the sample \((S = 1)\) (positivity):

\[
0 < \Pr(S = 1|W) < 1, \text{ for all } W, \text{ such that } P_T(W) > 0
\]

Third, we assume similar distribution of the versions of treatment in the study sample and the target population (of which treatment variation irrelevance is a
special case). This may be a strong assumption when the delivery mechanism for treatment differs dramatically between the study sample and the target population (e.g., treatment given to trial participants may have been accompanied by more adherence education and supportive services, as well as Hawthorne effects due to trial participation).\textsuperscript{11} Fourth, we assume similar patterns of interference in the target population and the study sample (of which no interference is a special case).\textsuperscript{11-13} Finally, we assume no measurement error for exposure, outcome, and all variables $W$, and correct model specification (if we use a parametric model).

**Defining the target population**

Failure to specify the target population explicitly precludes comparisons between the target population and the study sample of patient characteristics (exchangeability), details of the implementation of the intervention (treatment versions), or the comparison of patterns of interference between the target population and the study sample. In failing to make these aspects explicit in study design and planning, the generalizability of study results to some unspecified target population is nebulous.\textsuperscript{14-18}

There are several categories of choices for the target population.\textsuperscript{19} First, the study sample may be a census of the target population. This is almost never the case, because in nearly all instances, we have done research to inform decisions about a population at least somewhat different than that under study. A second choice for the target population may be the population from which the study sample was sampled. When the sampling is random, $P_S(W)$ is the same as $P_T(W)$ in expectation.
and sample average treatment effect equals the population average treatment effect in expectation (Figure 1a). When the study sample is not a random sample from the target population and \( P_S(W) \) differs from \( P_T(W) \), the sample average treatment effect can be expected to differ from the population average treatment effect (Figure 1b). A third choice for the target population is some other population that does not include the study sample (Figure 1c). In both of the latter cases (study sample not a random sample of the target; external population), additional information is needed to estimate the effect of interest in the target population, namely the distribution of \( P_T(W) \).

A distinction between generalizing results to a target population that includes as members those persons included in the study sample (Figures 1a and 1b) and transporting results to a target population that is non-overlapping with the study sample (Figure 1c) has been made previously, but not discussed in depth. In the former case, a physical probability of sampling can be envisioned; in the latter, the probability of sampling is not physical. This should not alarm us; transporting results to a target population that is non-overlapping with the study sample is simply direct standardization. Graphical criteria can assist in determining whether an estimate of effect is directly transportable and if not, can help identify the appropriate “transport formula” for estimating an effect for the target population. Despite these distinctions between target populations are overlapping or non-overlapping with the study sample, the same set of generalizability assumptions described above holds in both scenarios.
Example

To demonstrate how the sample average treatment differs from the population average treatment effect when the study sample is not a random sample of the target population, consider the following example. Imagine the target population comprises \( N = 50,000 \) individuals, in whom the prevalence of two dichotomous causes of the outcome, \( W_1 \) and \( W_2 \), is 0.15 and 0.20, respectively. In the study sample \( (n=1,000) \), as in many trials, participants at greater risk of the outcome \( (W_1 = 1 \) or \( W_2 = 1) \) were oversampled, with \( P(W_1) = 0.5 \) and \( P(W_2) = 0.5 \). In both the study sample and in the target population, the exposure, \( A \), is randomly assigned with probability 0.5. The 1-year risk for the outcome is defined by the function: \( P(Y = 1) = 0.1073 - 0.05A + 0.20W_1 + 0.20W_2 - 0.15AW_1W_2 \). The data from one realization of a target population and study sample generated under these conditions appears in Table 1.

Given this realization of the data, the estimate of the risk difference due to \( A \) in the target population is -5.3%. The estimate of the risk difference due to \( A \) in the study sample is -9.7%.

The g-formula or inverse probability (IP) of sampling weights can be used to use the study sample data to estimate the population average treatment effect. The g-formula (equivalent to Bareinboim & Pearl’s “transport formula”)\(^{23} \) and equation (1) above is:

\[
P[Y(a)] = \sum_W P[Y(a)|W = w]P_T(W = w)
\]
Which, if we assume consistency and conditional exchangeability given $W$, can be estimated by:

$$P[Y = 1|A = a] = \sum_w P[Y = 1|A = a, W = w] P_T(W = w)$$

where the quantity $P[Y = 1|A = a, W = w]$ is estimated in the study sample and $P_T(W = w)$ is the probability that $W = w$ in the target population. The estimate of the effect in the target population using the non-parametric g-formula was -5.4%.

Scaled IP of sampling weights were defined:

$$\frac{P(S = 1)}{P(S = 1|W_1 = w_1, W_2 = w_2)}$$

If the set of covariates, $W$, that should be included in calculating IP of sampling weights is high dimensional, the denominator of the weights can be modeled parametrically. In this example, we used a fully saturated model for the denominator of the weights. The IP of sampling weighted estimate of effect in the target population based on data from the study sample was -5.4%.

Note that the results from the IP of sampling approach and the g-formula/transport formula will be equivalent when both are estimated non-parametrically. In practice, if the dimension of $W$ is large and $P(S = 1)$ or $P(Y = 1|A = a, W = w)$ is modeled, the two approaches may give different results due to different modelling assumptions or model misspecification. Doubly robust estimation of the population average treatment effect is also possible.25

**Practical considerations for study design**

Generalizability Definitions
The only way to ensure an estimate is directly generalizable (in expectation) to a particular target population would be to draw the study sample as a random sample from that target population as described above.\textsuperscript{12} However, beyond the logistical, financial, and ethical challenges to conducting such a study, in certain circumstances, a study sample that is representative of the target population may be undesirable.\textsuperscript{18,26,27} When first exploring the existence of a causal effect, non-random sample selection may be purposefully undertaken. For example, an investigator might enroll a sample for a trial that has a higher than average risk of disease to increase statistical efficiency, or restrict enrollment into an observational study to control for an important confounder. Oversampling to avoid sparse numbers of patients within subgroups improves precision during confounder control and also allows estimation of subgroup effects,\textsuperscript{18,26} although trials are rarely powered to estimate such subgroup effects.

Epidemiologists are typically primarily concerned with the internal validity of effect estimates. However, the value of an effect estimate for planning purposes and decision making will depend on the degree of departure from both internal \textit{and} external validity. External validity will be threatened to the degree that 1) the prevalence of other causes of the outcome (also versions of treatment, patterns of interference) differs in the study sample and the target population, and 2) the exposure or intervention causal contrast is modified by those other causes of the outcome that differ in the study sample and the target population.\textsuperscript{2} For example, Greenhouse et al., describe a trial of antidepressants in adolescents that pointed to an increased risk of suicide, but which excluded participants with the most severe
depression who would have experienced the greatest benefits from the therapy. In this case, while the trial effects were internally valid, the lack of external validity had serious implications for policy and removed potentially beneficial treatment options from depressed adolescent patients. A second example is, the discrepancies between the conclusions about the effects of combined estrogen/progestin menopausal hormone replacement therapy (HRT) on coronary heart disease based on the Women’s Health Initiative trial and the Nurses’ Health Study can be recast as a generalizability problem if we consider that the age- and time-on-exposure stratum specific effects of HRT estimated in both studies were similar, but the distribution of women by age and time-on-exposure in the target population (young women with no prior exposure) did not match the distribution of women in the study sample from the Nurses’ Health Study (older women with lots of prior exposure). In this instance, while internal validity (confounding by some unmeasured factor) was initially blamed for the discrepancy, and while generalizability is typically only thought of as an issue for clinical trials, the generalizability of this observational study undermined policy recommendations based on its results. Such examples highlight the importance of balancing study design decisions to maximize both internal and external validity.

If our study sample is not a random sample of the target population, we can estimate causal effects in a specified target population using direct standardization or inverse probability weighting (a semiparametric extension of direct standardization) if all predictors of both selection into the study sample and the outcome are measured in both the study sample and the target population. This
methodological solution would allow us to use a single study sample to calculate
generalized estimates of effect for multiple different specified target
populations\textsuperscript{2,12,13} as long as the distribution of W was available for the target
population\textsuperscript{15,30}

**Discussion**

Commentaries on the lack of generalizability of randomized trials typically
implore the reader to evaluate a lengthy check list of potential determinants of
external validity\textsuperscript{,16,17,31} or further classify the list into categories to distinguish
“external validity” from “applicability.”\textsuperscript{32} We argue that such exercises could be
more efficient if considered quantitatively, within the potential outcomes
framework. This approach would quickly narrow the scope of future research
needed to ascertain the effect estimate of interest because specific threats to the
external validity of the estimate could be identified and used to guide future study
design. Furthermore, understanding the mechanism by which differences between
the sample and the target population influence the generalizability of a sample
estimate would help identify the most appropriate methods to account for those
differences. Understanding differences in the distribution of risk factors for the
outcome has implications for the selection of the study sample for future research.

Arguments about the generalizability of study results are not well-formed
until the relevant characteristics of the target population are explicitly stated (i.e.,
patient characteristics are designated or interference patterns are specified or the
types of therapy defined). This is analogous to the estimation of controlled direct
effects; such direct effects are not well-defined until the researcher specifies that the estimator is the direct effect not through M, where M is some possible mediator.\textsuperscript{33}

Finally, distinguishing internal and external threats to validity is useful for determining which parameters in the study sample or target population are estimable. When collider stratification bias due to selection is present in a study, it may threaten causal inference being made for any population,\textsuperscript{34} even the study sample, and preclude attempts to generalize results to either the source population or any specified target population (associational estimate is biased for the causal effect in the study sample; generalizability is irrelevant). In contrast, if a study can be determined to be free of selection bias (and confounding) (associational estimate is an unbiased estimate of the causal effect in the study sample) and differences in average treatment effects attributed to nonrandom sampling of the study population, methods exist to generalize results to a the target population (contingent on all assumptions outlined above).\textsuperscript{2,35} Standardizing effect estimates to the appropriate target population will improve their utility to clinicians and public health practitioners, and better inform implementation of interventions in target populations.

**Funding**

Dr. Westreich was supported in part by NIH grant DP2 HD084070. Dr. Cole and Dr. Lesko were supported in part by NIH grant R01 AI100654. Dr. Cole, Dr. Westreich and Dr. Hudgens were supported in part by NIH grant P30 AI50410. Dr. Buchanan was supported in part by NIH grants U01 AI103390-02, and R24 AI067039. The
content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**Acknowledgements**
References

Generalizability Definitions
Table 1. Data from a hypothetical target population ($N=50,000$) and nonrandom study sample ($n=1,000$)

<table>
<thead>
<tr>
<th>$Z_1$</th>
<th>$Z_1$</th>
<th>$A$</th>
<th>$Y$</th>
<th>$N$ (target)</th>
<th>$n$ (sample)</th>
<th>Scaled IP sampling weight\textsuperscript{a}</th>
<th>Weighted sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>15,023</td>
<td>68</td>
<td>4.239</td>
<td>288.2</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1807</td>
<td>11</td>
<td>4.239</td>
<td>46.6</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>16,046</td>
<td>75</td>
<td>4.239</td>
<td>317.9</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1,035</td>
<td>6</td>
<td>4.239</td>
<td>25.4</td>
</tr>
<tr>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>2,954</td>
<td>85</td>
<td>0.712</td>
<td>60.5</td>
</tr>
<tr>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1,285</td>
<td>35</td>
<td>0.712</td>
<td>24.9</td>
</tr>
<tr>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>3,221</td>
<td>91</td>
<td>0.712</td>
<td>64.7</td>
</tr>
<tr>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1,078</td>
<td>29</td>
<td>0.712</td>
<td>20.6</td>
</tr>
<tr>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2,087</td>
<td>88</td>
<td>0.506</td>
<td>44.5</td>
</tr>
<tr>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>914</td>
<td>28</td>
<td>0.506</td>
<td>14.2</td>
</tr>
<tr>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>2,285</td>
<td>88</td>
<td>0.506</td>
<td>44.5</td>
</tr>
<tr>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>787</td>
<td>36</td>
<td>0.506</td>
<td>18.2</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>360</td>
<td>84</td>
<td>0.082</td>
<td>6.9</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>378</td>
<td>97</td>
<td>0.082</td>
<td>8.0</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>517</td>
<td>125</td>
<td>0.082</td>
<td>10.3</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>223</td>
<td>54</td>
<td>0.082</td>
<td>4.4</td>
</tr>
</tbody>
</table>

\textsuperscript{a} Scaled inverse probability of sampling weight
Table 2. Summary data from a hypothetical target population \((N=50,000)\) and crude and inverse probability of sampling weighted nonrandom study sample \((n=1,000)\)

<table>
<thead>
<tr>
<th></th>
<th>Target population</th>
<th>Study sample</th>
<th>Weighted sample</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(Y = 0) (Y = 1) Risk</td>
<td>(Y = 0) (Y = 1) Risk</td>
<td>(Y = 0) (Y = 1) Risk</td>
</tr>
<tr>
<td>(X = 0)</td>
<td>20,424 4,384 0.177</td>
<td>X = 0 325 171 0.345</td>
<td>X = 0 400 94 0.190</td>
</tr>
<tr>
<td>(X = 1)</td>
<td>22,069 3,123 0.124</td>
<td>X = 1 379 125 0.248</td>
<td>X = 1 437 69 0.136</td>
</tr>
<tr>
<td>RD: (X = 0)</td>
<td>-0.053</td>
<td>RD: -0.097</td>
<td>RD: -0.054</td>
</tr>
<tr>
<td>RR:</td>
<td>0.702</td>
<td>RR: 0.719</td>
<td>RR: 0.716</td>
</tr>
</tbody>
</table>
Figure 1. Possible choices for the target population of interest

1a: The study sample is a random sample from the target population.

1b: The study sample is not a random sample from the target population.

1c: The target population is external to the study sample.

The target population (large, light gray square) can relate to the study sample (small, dark gray circle) in multiple ways. (a) The study sample is a random sample from the target population. (b) The study sample is not a random sample from the target population. (c) The target population is external to the study sample. The target population can be described by either a census of the target population or a random sample of the target population (small, dark gray square). In situation (b) or (c), the study sample can be thought of as a random sample from a larger super-population (larger, light gray circle) that differs from the target population; if the analysis does not standardize or transport results to the target population, inference is restricted to this super-population.